Approximately 2.85 million people in the US suffer from heart failure with reduced ejection fraction(HFrEF)1
Nearly 1 in 5 patients with HFrEF progress to worsening heart failure* within 1.5 years after initial diagnosis2
Survival probability steadily decreases over time following each worsening heart failure event3
Each subsequent hospitalization for heart failure increases a patient's risk for all-cause mortality6
- In the US alone, >1 million hospitalizations occur annually for heart failure, with approximately half of these patients readmitted within 6 months of discharge. Nearly 30% of these patients die within one year3
- Heart failure is the most frequent cause of hospitalization in people ≥65 years7
Left ventricular ejection fraction (LVEF) is an important prognostic factor used to classify the severity of patients with worsening heart failure
- HFrEF is defined as LVEF ≤40% by 2022 AHA/ACC/HFSA heart failure guidelines4
Patients with heart failure who present declining ejection fractions and elevated NT-proBNP levels are at greater risk for an event9,10
In addition to LVEF, consider the value of NT-proBNP. With it, you can4,9:
- Diagnose heart failure
- Determine heart failure risk stratification
- Establish prognosis at hospital discharge
Patients with worsening heart failure often have multiple comorbidities, making SOC optimization a challenge12
- Most patients with HFrEF typically have ≥3 comorbidities that require treatment13
- Often, patients with heart failure do not reach optimal SOC doses due to tolerability issues3,14,15§
- More than half of heart failure patients age ≥65 years are receiving ≥10 medications following an event16
Many comorbidities accompany heart failure17
Adapted from Khan MS et al. Eur J Heart Fail. 2020.
In an observational cohort analysis, the use of beta-blockers decreased (69.7% of patients were receiving them 3 months prior to a worsening HF event, to 69.1% 6 months after the event) and ACEi/ARB (46.5% to 46.0%) likewise decreased. Use of MRA therapy remained consistently low (21.8% to 24.7%) across the study.
Patients who have experienced a worsening heart failure event reported greater treatment burden and reduced quality of life2¶
*Worsening heart failure was characterized by worsening signs/symptoms of heart failure or hospitalization from heart failure.
†Proportion of patients with cardiovascular death or heart failure hospitalization is aggregate data from the CHARM Program (CHARM-Alternative, CHARM-Added, and CHARM-Preserved pivotal trials) evaluating the efficacy and safety of candesartan in patients with New York Heart Association Class II to IV heart failure.2 Because the CHARM Program predates newer therapies for the treatment of HFrEF (eg, SGLT2i, ARNI), current rates for cardiovascular death or heart failure hospitalization may vary.
‡Adjusted hazard ratio per 100 patient-years for each 10% reduction in LVEF <45% is 1.21 (95% CI, 1.15-1.28).
§SOC may include a RAAS inhibitor (ARNi, ACEi, ARB), Beta Blocker, MRA, SGLT2 inhibitor, and/or other medication.
¶Results from recent bivariate analyses.
ACC, American College of Cardiology; AHA, American Heart Association; EF, ejection fraction; HFSA, Heart Failure Society of America; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; SOC, standard of care.